TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26271050
Drug: Single-dose ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose ciprofloxacin treatment for nalidixic acid-resistant strains
Study: 26271050
Drug: Multiple-dose ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple-dose ciprofloxacin treatment for nalidixic acid-susceptible strains
Study: 26271050
Drug: Multiple-dose ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple-dose ciprofloxacin treatment for nalidixic acid-resistant strains
Study: 21414384
Drug: Circumferential matrix
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Circumferential matrix system in combination with a retainer (Tofflemire)
Study: 17144123
Drug: Indomethacin in
Normalized name: indomethacin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin in usual doses (administered in addition to standard therapy)
Study: 17144123
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (without indomethacin)
Study: 14512803
Drug: Poly E
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poly E ointment applied locally to 27 patients twice a week
Study: 14512803
Drug: Poly E
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poly E ointment plus poly E capsule therapy
Study: 14512803
Drug: Poly E
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poly E capsule therapy
Study: 14512803
Drug: EGCG capsule
Normalized name: EGCG
DrugBank: Epigallocatechin gallate (DB12116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGCG capsule therapy
Study: 14512803
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment with green tea extracts
Study: 7996367
Drug: IVIG (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG (500 mg/kg)
Study: 9179429
Drug: Inhaled magnesium
Normalized name: Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled magnesium sulphate (180 mg)
Study: 8473554
Drug: Experimental lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental lipid emulsion formulation of danazol (fasted)
Study: 8473554
Drug: Commercial formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial formulation (hard gelatin capsule) (fasted)
Study: 8473554
Drug: Commercial formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial formulation (hard gelatin capsule) (fed)
Study: 8473554
Drug: Experimental lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental lipid emulsion formulation of danazol (with food)
Study: 23839118
Drug: Local lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local lidocaine injection
Study: 19199072
Drug: Local saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local saline injection (control)
Study: 7856527
Drug: Stable background
Normalized name: Heat stable ricin vaccine
DrugBank: Heat stable ricin vaccine (DB18477)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stable background therapy
Study: 31648501
Drug: Apatinib combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib combined with standard first-line chemotherapy
Study: 26215950
Drug: Paclitaxel alone
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel alone (90 mg/m² per week for six cycles of 28 days each; arm A)
Study: 26215950
Drug: Paclitaxel combined
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel combined with bevacizumab (10 mg/kg once every 2 weeks; arm B)
Study: 24268858
Drug: Low‐fluence photodynamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low‐fluence photodynamic therapy (PDT)
Study: 22172912
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid gel (RadiaPlex)
Study: 22172912
Drug: Petrolatum gel
Normalized name: Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Petrolatum gel (Aquaphor)
Study: 19240602
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for unruptured MCA aneurysms
Study: 19240602
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for ruptured MCA aneurysms
Study: 19240602
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for both unruptured and ruptured MCA aneurysms
Study: 8726155
Drug: Metered Dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered Dose Inhaler (MDI) - 2 puffs or 200 micrograms
Study: 1559290
Drug: Daily wear
Normalized name: ZINC OXIDE 22.7 g in 100 g TOPICAL LOTION [ETHICAL ZINC DAILY WEAR LIGHT SUNSCREEN SPF-50]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily wear or extended wear schedule
Study: 30411125
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health promotion project (6 months duration)
Study: 31967678
Drug: Hyperthermic intraperitoneal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperthermic intraperitoneal chemotherapy (HIPEC) added to interval cytoreductive surgery (CRS)
Study: 20495139
Drug: Phenylephrine 75
Normalized name: GUAIFENESIN 400MG/PHENYLEPHRINE 75MG TAB,SA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine 75 μg/min
Study: 20495139
Drug: Phenylephrine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine (all doses)
Study: 19114405
Drug: COF (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: COF (250 mL of black coffee)
Study: 19114405
Drug: COF+SUC (black
Approvals — FDA: no, EMA: no, PMDA: no
Description: COF+SUC (black coffee sweetened with 10 g of sucrose)
Study: 19114405
Drug: SUC (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: SUC (10 g sucrose)
Study: 15953302
Drug: Therapist-administered relaxation
Normalized name: endothelium-derived relaxing factor
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Therapist-administered relaxation training
Study: 15953302
Drug: School-nurse administered
Normalized name: schorl tourmaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: School-nurse administered relaxation training
Study: 10029463
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of the most sensitive clinical items
Study: 8985221
Drug: Meningococcal polysaccharide
Normalized name: meningococcal polysaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningococcal polysaccharide vaccine
Study: 1745841
Drug: Bromhexine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromhexine (30 mg capsules three times daily)
Study: 1745841
Drug: Placebo (matched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matched placebo capsules)
Study: 7050705
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal (180 g) in divided doses over three days after phenobarbital infusion
Study: 31060589
Drug: Psychologically informed
Normalized name: INFORMATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychologically informed physical therapy (PIPT) training program
Study: 24691853
Drug: Topical sucralfate
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical sucralfate four times a day for 7 days
Study: 19846848
Drug: Higher-intensity continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-intensity continuous renal-replacement therapy (40 ml/kg/hour)
Study: 19846848
Drug: Lower-intensity continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-intensity continuous renal-replacement therapy (25 ml/kg/hour)
Study: 19846848
Drug: Higher-intensity continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-intensity continuous renal-replacement therapy
Study: 19846848
Drug: Lower-intensity continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-intensity continuous renal-replacement therapy
Study: 17367361
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups after the first month post-implant
Study: 16379582
Drug: Anatibant 3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anatibant 3.75 mg
Study: 16379582
Drug: Anatibant 22.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anatibant 22.5 mg
Study: 16379582
Drug: Anatibant (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anatibant (both doses)
Study: 2504034
Drug: Lithium (Li)
DrugBank: Lithium succinate (DB14508)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium (Li) added to tricyclic antidepressant
Study: 975039
Drug: Weekly combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly combination chemotherapy
Study: 975039
Drug: Intermittent combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent combination chemotherapy
Study: 975039
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (both weekly and intermittent)
Study: 30560426
Drug: Synbiotic capsule
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic capsule (Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum, 2 × 10^9 CFU/g each, plus 0.8 g/day of inulin)
Study: 30560426
Drug: Synbiotic capsule
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic capsule
Study: 28459958
Drug: TRV027 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRV027 5 mg/h
Study: 28459958
Drug: TRV027 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRV027 25 mg/h
Study: 26036529
Drug: Steroid-free regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-free regimen (tacrolimus, mycophenolic acid, basiliximab induction, steroids for 3 days)
Study: 26036529
Drug: Steroid maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid maintenance regimen (tacrolimus, mycophenolic acid, basiliximab induction, steroids maintenance)
Study: 26036529
Drug: Steroid maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid maintenance regimen
Study: 22384550
Drug: Weifuchun Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weifuchun Pill
Study: 19211408
Drug: EUSOL (Edinburgh
Approvals — FDA: no, EMA: no, PMDA: no
Description: EUSOL (Edinburgh University Solution of Lime)
Study: 8026054
Drug: Intracoronary urokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary urokinase (250,000 U in divided doses)
Study: 8026054
Drug: Intracoronary urokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary urokinase (500,000 U in divided doses)
Study: 4138966
Drug: CCNU (130
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCNU (130 mg/m2 orally every 6 weeks)
Study: 4138966
Drug: 5 azacytidine
Normalized name: 5 azacytidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 azacytidine (60 mg/m2 intravenously daily for 10 days and twice weekly thereafter)
Study: 4138966
Drug: Cyclophosphamide (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (two dose schedules)
Study: 26154454
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) application (6J)
Study: 23454058
Drug: Boceprevir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boceprevir (400 mg TID)
Study: 18434021
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose (1 ml, 25%)
Study: 12971247
Drug: Novel agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel agents and/or combination therapies
Study: 10233189
Drug: RBC400OM: RBC
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC400OM: RBC 400 mg b.d., oxytetracycline 500 mg q.d.s.
Study: 10233189
Drug: RBC400SM: RBC
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC400SM: RBC 400 mg b.d., spiramycin 1 g q.d.s.
Study: 10233189
Drug: RBC200OM: RBC
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC200OM: RBC 200 mg q.d.s., oxytetracycline 500 mg q.d.s.
Study: 10233189
Drug: RBC200SM: RBC
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC200SM: RBC 200 mg q.d.s., spiramycin 1 g q.d.s.
Study: 9119918
Drug: Risperidone 4-16
Normalized name: risperidone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 4-16 mg/day
Study: 9119918
Drug: Haloperidol 10-20
Normalized name: haloperidol 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 10-20 mg/day
Study: 31230881
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose formulation of the EV71 vaccine
Study: 31230881
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose formulation of the EV71 vaccine
Study: 20229041
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of E. coli lipopolysaccharide (LPS) at a dosage of 0.3 ng/kg
Study: 20229041
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of E. coli lipopolysaccharide (LPS)
Study: 8778004
Drug: Anti-fetal lymphocyte
Normalized name: lymphocyte immune globulin, anti-thymocyte globulin
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-fetal lymphocyte cytotoxic antibodies (AFCA) detection using complement dependent microcytotoxicity assay
Study: 3149202
Drug: Pirenzepine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (10 mg intravenous bolus followed by 2.5 mg/h continuous infusion)
Study: 23782962
Drug: Flu-50 (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flu-50 (0.5 ml)
Study: 23782962
Drug: Flu-25 (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flu-25 (0.25 ml)
Study: 23782962
Drug: Control vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control vaccine (Fluzone®; 0.25 ml)
Study: 18695440
Drug: Eptifibatide and
Normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eptifibatide and unfractionated heparin according to the ESPRIT protocol
Study: 18695440
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and unfractionated heparin
Study: 16109110
Drug: Acetaminophen (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (500 mg), Aspirin (500 mg), Caffeine (130 mg)
Study: 9495394
Drug: Positive inotropic
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive inotropic drugs (PIDs) including amrinone, dobutamine, epinephrine, or dopamine (≥ 5 microg x kg[‐1] x min[‐1])
Study: 9495394
Drug: Positive inotropic
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive inotropic drugs (PIDs)
Study: 24559015
Drug: 200 mL
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mL of an oral nutritional supplement containing maltodextrine and whey protein, consumed 150 to 210 min before gastroscopy
Study: 23098412
Drug: Ibuprofen 600
Normalized name: ibuprofen 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 600 mg three times daily before and during ascent to 4928 m
Study: 17986746
Drug: RBC‐AT (Ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC‐AT (Ranitidine Bismuth Citrate 400 mg, Amoxicillin 1000 mg, Tetracycline 500 mg)
Study: 17986746
Drug: RBC‐AC (Ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC‐AC (Ranitidine Bismuth Citrate 400 mg, Amoxicillin 1000 mg, Clarithromycin 500 mg)
Study: 17986746
Drug: RBC‐MT (Ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC‐MT (Ranitidine Bismuth Citrate 400 mg, Metronidazole 500 mg, Tetracycline 500 mg)
Study: 9678816
Drug: Bismuth subnitrate
Normalized name: Bismuth subnitrate
DrugBank: Bismuth subnitrate (DB13209)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth subnitrate (300 mg q.d.s.), omeprazole (20 mg b.d.), and amoxycillin (500 mg q.d.s.) for 14 days
Study: 9678816
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg b.d.) and amoxycillin (500 mg q.d.s.) for 14 days
Study: 9678816
Drug: Bismuth subnitrate
Normalized name: Bismuth subnitrate
DrugBank: Bismuth subnitrate (DB13209)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth subnitrate with dual oral therapy
Study: 9678816
Drug: Dual oral
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual oral therapy alone
Study: 31837559
Drug: Rivaroxaban 20
Normalized name: rivaroxaban 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 20 mg once daily (OD) for 6 months, started on day 3 postoperatively
Study: 31837559
Drug: Rivaroxaban 20
Normalized name: rivaroxaban 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 20 mg OD
Study: 24130350
Drug: HCLC followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HCLC followed by SAP therapy (intensive group; N = 48)
Study: 24130350
Drug: Usual-care group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual-care group treated with multiple daily injections or insulin pump therapy (N = 20)
Study: 24130350
Drug: HCLC followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HCLC followed by SAP therapy (intensive group)
Study: 20955776
Drug: Citalopram (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (10 mg twice a day for 5 days)
Study: 16781295
Drug: Finasteride (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride (1 mg daily)
Study: 1884747
Drug: Rythmodan L.A.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rythmodan L.A. 250 mg b.d.
Study: 1884747
Drug: Dirytmin Durettes
Normalized name: CUVETTES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dirytmin Durettes 300 mg b.d.
Study: 6819898
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of metoclopramide and lisuride
Study: 29053808
Drug: Age-Related Eye
Normalized name: casein, Lactococcus lactis cultured, aged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age-Related Eye Disease Study 2 formulation with a low dose [25 mg] of zinc and an addition of 10 mg meso‐zeaxanthin; n = 60
Study: 29053808
Drug: Age-Related Eye
Normalized name: casein, Lactococcus lactis cultured, aged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age-Related Eye Disease Study 2 formulation with a low dose [25 mg] of zinc; n = 61
Study: 14747781
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no contraceptive steroid)
Study: 12659397
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive (30 microgram ethinylestradiol and 150 microgram desogestrel)
Study: 7472661
Drug: Low nitrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low nitrogen and low calcium diet (0.49 +/- 0.11 g protein/(kg.d), 429 +/- 190 mg calcium/d)
Study: 7472661
Drug: Low nitrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low nitrogen and high calcium diet (0.44 +/- 0.08 g protein/(kg.d), 1643 +/- 171 mg calcium/d)
Study: 7472661
Drug: High nitrogen
Normalized name: Isosource High Nitrogen Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: High nitrogen and high calcium diet (2.71 +/- 0.75 g protein/(kg.d), 1589 +/- 633 mg calcium/d)
Study: 7472661
Drug: Baseline dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline dietary intake (0.99 +/- 0.51 g protein/(kg.d), 589 +/- 152 mg calcium/d)
Study: 6791396
Drug: Sublingual administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual administration of 1.6 mg of nitroglycerin (Group I)
Study: 27563883
Drug: Hormone Therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone Therapy (HT) - 1 mg/day of estradiol valerate plus 5 mg/10 day of medroxiprogesterone
Study: 23917935
Drug: Placebo (gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (gel with the same color and consistency and toothbrushing)
Study: 18276619
Drug: Anti-Xa levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-Xa levels > 0.9 IU/mL
Study: 14623061
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg estradiol plus 1 mg norethindrone acetate
Study: 11003744
Drug: Platelet activating
Normalized name: Platelet activating factor
DrugBank: Platelet Activating Factor (DB02261)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet activating factor antagonist (low-dose 10 mg or high-dose 100 mg)
Study: 1443350
Drug: Albendazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (400 mg/day for 10 days)
Study: 6536515
Drug: Both drugs
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both drugs (Midazolam and Diazepam)
Study: 23650913
Drug: Prophylactic endoscopic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic endoscopic injection sclerotherapy (EIS)
Study: 20507401
Drug: Ciprofloxacin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (250 mg) every 12 hours for 6 months
Study: 10733017
Drug: Leuprorelin 3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprorelin 3.75 mg (n=33)
Study: 10733017
Drug: Lynestrenol 5
Normalized name: lynestrenol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lynestrenol 5 mg (n=23)
Study: 8817830
Drug: Plasmodium falciparum
Normalized name: Plasmodium falciparum Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasmodium falciparum circumsporozoite protein vaccine
Study: 1306086
Drug: Diapulse therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diapulse therapy (pulsed electromagnetic energy of 27.12 MHz frequency)